Blogs

1 person recommends this.
I am friends with the author of this blog, Carolyn Thomas, and with her permission I am copying it in its entirety here  but I encourage you to share the link to her post with the people who make decisions on including patients in conferences.    https://myheartsisters.org/2016/03/06/my-open-letter-to-patients-included-conferences/ You will also have to go to her site to get the original formatting and possibly to follow the many links she has included.   best, Laura Dear medical conference organizers, Thank you so much for inviting me to participate in your conference later this year. It is a real honour to be asked to help represent  the patient ...
0 comments
Be the first person to recommend this.
We all know that patient engagement is essential. Take the Pledge to patients – a commitment to more meaningful patient engagement in medicines development - and make it happen!,  Are YOU ready to commit? Sign your pledge right now at www.patientfocusedmedicine.org They have signed their pledge and set personal objectives for better patient engageme
0 comments

Patient Engagement

Be the first person to recommend this.
The FDA established a public docket to solicit input on ongoing efforts to enhance mechanisms for Patient engagement at the Agency. Engaging with patients, their caregivers, and advocates has long been a priority of the Agency. In this tradition, FDA intends to enhance future patient engagement by providing a more transparent, accessible, and robust experience for patient communities. To achieve these goals, FDA is considering establishing a new Office of Patient Affairs. This concept was directly informed by the public feedback solicited through the prior public docket regarding FDA's stakeholder engagement responsibilities outlined by the Food and Drug Administration ...
0 comments
Be the first person to recommend this.
On 1 March 2017, the Vice-President of the Court of justice issued a ruling that sets up the opportunity for a much needed final adjudication of the parameters of commercially confidential information within clinical trial data. [1] Background To recap briefly on the facts of this case, PTC Therapeutics obtained a conditional orphan marketing authorisation ( MA ) for Translarna for the treatment of muscular dystrophy. Translarna was granted a conditional MA in May 2014 as an orphan product. Following the grant of this conditional MA, in October 2015 the EMA received an access to documents request pursuant to Regulation 1049/2001/EC (the Transparency ...
0 comments
1 person recommends this.
Just when I thought the patient experience and our voice was being considered and respected as a serious partner to the drug industry, I get that reality call to take off the rose colored glasses. This time the splash of cold water to bring me back to my senses came via a tweet from a respected person in the patient advocacy field.This person had received an electronic newsletter from Clinical Leader, a group that states they are the "premier online community that helps streamline clinical research by connecting trial sponsors and cutting edge service providers." and when the headline ' The Anatomy of the Ideal Clinical Trial Participant' was selected, ...
2 comments
3 people recommend this.
Like every other Project Manager I know, I have a thousand demands on my time. Why do I choose to be a part of the DIA Project Management Community? I got involved in DIA back in 2008, as a session chair at the Annual Meeting. I was looking for opportunities to present on PM topics, and DIA seemed like the ideal meeting to meet other professionals who worked in the pharmaceutical industry. The meeting exceeded my expectations - so much to see and learn, and so many experienced people to meet and network with - and I was bitten by the Annual Meeting 'bug'. I really enjoyed presenting, talking with other PMs who faced similar challenges in ...
0 comments
2 people recommend this.
Global Project Management Colleagues: It's already March and about 3-1/2 months from this year's DIA Annual Meeting in Philadelphia (June 26-30). I hope as many of you are planning to attend as possible! This year's program will offer some new opportunities for learning, networking, as well as feature a very strong Project/Portfolio Management track. Here are a few highlights: 1. The Project/Portfolio Management track will offer sessions in drug development from different therapeutic areas, maximizing the value of your product, decision-making, expanded access, CMC, international price referencing and leadership. 2. The addition of multiple plenary ...
0 comments

Off-Label Communications

Be the first person to recommend this.
by Peter J. Pitts Reposted from the DIA Collaborate to Innovate Blog The debate over off-label communications doesn’t begin or end with the Caronia or Amarin decisions. It’s a continuing dialogue between manufacturers and the FDA, between doctors and patients, between doctors and academics, between lawyers and judges, and between advocates on all sides. And the red thread that ties these conversations together is responsible off-label communications. Not sales strategies. Not DTC tactics. Not managed market negotiations – the responsible sharing of truthful and accurate information. It’s important to say early in the conversation that ...
0 comments
Be the first person to recommend this.
A recent article by Shashi Amur and FDA colleagues on the future of biomarker development ( Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization — http://onlinelibrary.wiley.com/doi/10.1002/cpt.136/abstract ) provides a solid foundation for ongoing development and review process for biomarker qualification. FDA should be applauded for their progress in agency collaboration with the Critical Path Institute (in biomarker consortia development), the recent total kidney volume and plasma fibrinogen prognostic marker approvals, and sponsorship of interactive sessions such as the recent ...
0 comments